Study Evaluating GAP-486 in Heart Rhythm

Phase 2TerminatedNCT00137293

Wyeth is now a wholly owned subsidiary of Pfizer30 enrolled

Overview

The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Arrhythmia

Interventions

GAP-486 (ZP-123)DRUG

0.9% Sodium Chloride, USPDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients undergoing an electrophysiology study for evaluation of heart rhythm. Exclusion Criteria: * Patients with uncontrolled blood pressure * Patients with certain cardiac risk factors * Patients with significant kidney or liver problems

Locations (7)

Unnamed facility

San Francisco, California, United States

Unnamed facility

Washington D.C., District of Columbia, United States

Unnamed facility

Hershey, Pennsylvania, United States

Unnamed facility

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.

Secondary Outcomes

This study takes place within 24 hours, and looks at the changes in values of electrophysiology studies, before and after administration of test article.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.